Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — LifeSci Advisors Nordic BioTech Summit 2021
22 slides from Cantargia Ab's conference presentation, Jun 29, 2021
Slide 1: We want to save patients with severe cancer and autoimmune diseases
We want to save patients with severe cancer and autoimmune diseases Clinical investigations with our lead antibody CAN04 to our proprietary target Göran Forsberg, CEO June 2021
Slide 2: Safe Harbour Statement
Safe Harbour Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known an
Slide 3: I. Introduction
I. INTRODUCTION
Slide 4: Cantargia – Opportunity to save lives and create value
Cantargia – Opportunity to save lives and create value ➢ Potentially more effective treatment against novel target in clinically validated pathway ➢ First in class platform technology against novel target ➢ Well financed to build a broad, diversified pipeline ➢ Right team and clear plan to position
Slide 5: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors • Positive clinical interim data – PFS, durable responses and Current owners (31 Mar 2021) pseudoprogression Swedbank Robur Funds 9.7% VISION OF BECO
Slide 6: II. Lead Antibody Nadunolimab (CAN04)
II. LEAD ANTIBODY NADUNOLIMAB (CAN04)
Slide 7: CAN04 – Mechanism of action
CAN04 – Mechanism of action ADCC – Reduced activation Reduced Tumor cell death and infiltration of angiogenesis immunosuppressive cells CAN04 BLOCKS BOTH FORMS OF IL-1 AND CAN ERADICATE CELLS MEDIATING THE EFFECTS OF IL-1 Note: ADCC = Antibody-Dependent Cellular Cytotoxicity. CAF = Cancer-Associated
Slide 8: CAN04 – Differentiated and superior MOA
CAN04 – Differentiated and superior MOA Cancer context IL-1α IL-1β comment Localization • Cellbound and soluble • Soluble • IL-1α trigger and IL-1β • Cancer cells and stroma enhance inflammation • Often work in pair Function • Stimulates inflammation - IL1R1 -forming complex with IL1RAP • No known d
Slide 9: Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020)
Targeting IL1RAP allows unique synergistic effects with chemotherapy (AACR 2020) → Upregulation of both forms of IL-1 in PDX-model as response to Gem/Cis → IL-1α (DAMP) on cancer cells trigger inflammasome activation in tumor microenvironment (e.g. IL-1β) → CAN04 increases efficacy of Pt based chemo
Slide 10: Positive data in pancreatic cancer
Positive data in pancreatic cancer Efficacy evaluation summary: • Durable responses observed • Promising PFS and OS • Important finding of pseudoprogression-like response in 5 (15%) patients predicting long PFS. → CAN04 in combination with gem/abraxane in 1st line → 27% confirmed responses, 15% pseu
Slide 11: Patients with Pseudoprogression-like response
Patients with Pseudoprogression-like response Subject 1 Subject 2 • All presented PD at 1st CT scan evaluation (8 weeks) • All showed concomitant Ongoing reduction of CA19-9 Subject 3 Subject 4 Subject 5 Ongoing PSEUDOPROGRESSION VERY UNCOMMON IN PANCREATIC CANCER INDICATE IMMUNE RELATED MECHANISM O
Slide 12: Progression Free Survival (iRECIST) and overall survival
Progression Free Survival (iRECIST) and overall survival • Median iPFS is 7.8 months (95% CI 5.2 to 10.2) with 55% of events. • Median OS is 12.6 months (95% CI not estimable) with 42% of OS events. • Seven patients at cut-off are still receiving treatment. OS and iPFS longer than expected from chem
Slide 13: CAN04/GN in PDAC safety summary and benchmark
CAN04/GN in PDAC safety summary and benchmark Gem/Abraxane CANFOUR FOLFIRINOX Grade 3 or higher AEs (von Hoff) CAN04/GN (Conroy 2011) The beneficial effect in N=421 N=36 N=171 fatigue and chemotherapy- Neutropenia 38% 67% 46% induced neuropathy2 (nab- paclitaxel or oxaliplatin) Febrile neut
Slide 14: Tumor shrinkage – NSCLC combination
Tumor shrinkage – NSCLC combination → CAN04 in combination with gem/cis in 1st line chemotherapy Patient → 6 of 9 evaluable patients with metastatic non-small cell lung 1 2 3 4 5 6 7 8 9 0 cancer (NSCLC) showed objective response including 1 Percent tumor reduction complete response (67% vs historic
Slide 15: CIRIFOUR Phase I clinical trial
CIRIFOUR Phase I clinical trial → First patient started 2020, results expected H2 2021 → Combination with checkpoint inhibitor in patients no longer responding to PD1/PDL-1 therapy → Primary endpoint safety, secondary endpoints include biomarkers and efficacy → Indications include NSCLC, HNSCC, mali
Slide 16: Nadunolimab clinical development status
Nadunolimab clinical development status Study Indication CAN04 combination Status Planned milestone(s) CANFOUR NSCLC Gemcitabine/cisplatin Recruitment ongoing, Results planned for Q3 2021 CANFOUR PDAC Gemcitabine/nab- Extension phase ongoing. Main study results presented 20 May paclitaxel (Dosing sc
Slide 17: III. Untapped possibilities in autoimmune diseases
III. UNTAPPED POSSIBILITIES IN AUTOIMMUNE DISEASES
Slide 18: CAN10 – New development project
CAN10 – New development project → IL1RAP binding antibody potently blocking IL-1, IL-33 and IL-36 → Unique anti-inflammatory activity observed in different mouse models (myocarditis, psoriasis, inflammation) → Development focusing on unmet medical need in systemic sclerosis and myocarditis. Disease
Slide 19: mCAN10 improves heart function in experimental autoimmune myocarditis
mCAN10 improves heart function in experimental autoimmune myocarditis STRONG SUPPORT FOR SELECTION OF DEVELOPMENT STRATEGY 11
Slide 20: IV. Milestones and summary
IV. MILESTONES AND SUMMARY
Slide 21: Cantargia reached several milestones and have several value inflection points in near future
Cantargia reached several milestones and have several value inflection points in near future Newsflow over next 6–9 months CAN04 → New results PDAC, NSCLC and Keytruda combination → Next steps combination therapy PDAC and NSCLC → Phase IIa biomarker/biopsy results → Start new clinical trials • FOLFI
Slide 22: Cantargia highlights
Cantargia highlights UNIQUE IMMUNOTHERAPY ANTIBODY CAN04 IN PHASE IIA CLINICAL DEVELOPMENT • First in class antibody with broader MOA than competitors • Positive interim data set and further clinical milestones during 2021 VISION OF BECOMING AN IMPORTANT PART IN FUTURE CANCER TREATMENTS • Combinatio
Cantargia — LifeSci Advisors Nordic BioTech Summit 2021 on 6ix